Loading Events

Upcoming Events › Grant

Events Search and Views Navigation

Event Views Navigation

June 2020

NIH R21, R03

June 16
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

July 2020

Cycle 1: Alzheimer’s Drug Discovery Foundation

July 10
|Recurring Event (See all)

One event on July 10, 2020 at 12:00 am

One event on October 9, 2020 at 12:00 am

LOI Due Dates:

  • Cycle 1: April 10, 2020
  • Cycle 2: July 10, 2020
  • Cycle 3: October 9, 2020

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

July 12
|Recurring Event (See all)

One event on January 10, 2021 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 12, 2020, January 10, 2021
Application Due Date: August 11, 2020, February 9, 2021
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »

September 2020

BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3)

September 21
|Recurring Event (See all)

One event on September 21, 2020 at 12:00 am

Sponsor: National Institutes of Health
LOI Due Dates: May 23, 2020, September 21, 2020
Application Deadlines: June 22, 2020, October 21, 2020
Award: The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $2M per year.The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study).

Find out more »

AES Research and Training Workshops

September 23
|Recurring Event (See all)

One event on September 23, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Dates: 

  • Cycle 1: May 4, 2020
  • Cycle 2: September 23, 202o

Award: AES welcomes applications for funding to support scientific conferences and workshops focused on epilepsy research and training. Applications for workshop funding are reviewed by the AES Research and Training Council, and the number and amount of awards made each year are contingent on available funds.

Find out more »

AES Seed Grant Program 

September 28
|Recurring Event (See all)

One event on September 28, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Dates: 

  • Cycle 1: May 4, 2020
  • Cycle 2: September 28, 2020

Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

Broad PCORI Funding Announcements

September 29

Sponsor: Patient-Centered Outcomes Research Institute
LOI Due Date: September 29, 2020 at 5pm ET
Application Due Date: January 12, 2021 at 5pm ET
Award: The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research

Find out more »

October 2020

Cycle 1: Alzheimer’s Drug Discovery Foundation

October 9
|Recurring Event (See all)

One event on July 10, 2020 at 12:00 am

One event on October 9, 2020 at 12:00 am

LOI Due Dates:

  • Cycle 1: April 10, 2020
  • Cycle 2: July 10, 2020
  • Cycle 3: October 9, 2020

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

NIH R21, R03

October 16
|Recurring Event (See all)

One event on February 16, 2020 at 12:00 am

One event on June 16, 2020 at 12:00 am

One event on October 16, 2020 at 12:00 am

DUE DATES: 

  • Cycle 3: October 16, 2019 by 5 PM of local organization time
  • Cycle 1: February 16, 2020 by 5 PM of local organization time
  • Cycle 2: June 16, 2020 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

December 2020

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Award

December 31

Sponsor: International Rett Syndrome Foundation (IRSF)
Due Date: Applications accepted on a rolling basis
Award: Up to $600,000 over two years. Grant awards must be comprised of very specific programs that are focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates.

Find out more »

Rolling Basis: Alzheimer’s Drug Discovery Foundation

December 31

PROPOSALS ACCEPTED ON A ROLLING BASIS
ADDF/NIH
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Conference Funding
Supports scientific conferences that are relevant to our mission with grants up to $10,000.

Find out more »

January 2021

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

January 10, 2021
|Recurring Event (See all)

One event on January 10, 2021 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 12, 2020, January 10, 2021
Application Due Date: August 11, 2020, February 9, 2021
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »
+ Export Events